Q3 2020 Sales Performance

New environmental targets announced November 2020 gsk Climate action Net zero impact on climate by 2030 Biopharma • Net zero emissions across all operations by 2030 (scope 1 and 2) 100% renewable electricity by 2025 (scope 2) . • Net zero emissions across our full value chain by 2030 (scope 3) • • Consumer Healthcare Net zero emissions across all operations by 2030 (scope 1 and 2) 100% renewable electricity by 2025 (scope 2) Net zero emissions for select brands/formats by 2030 (scope 3) Nature Action Positive impact on nature by 2030 Biopharma 100% sites to achieve good water stewardship by 2025 and reduce overall water use by 20% by 2030 • Water neutral in operations and key suppliers in water stressed regions by 2030 • • Zero impact active pharmaceutical ingredient levels() for all sites and key suppliers by 2030 Zero operational waste, including eliminating single use plastics (2), by 2030 25% environmental impact reduction for our products and packaging by 2030 10% waste reduction from supply chain by 2030 • Positive impact on biodiversity at all sites (3) by 2030 • 100% materials sustainably sourced and deforestation free by 2030 Accredited 1.5 C SBTI reduction target; RE100 and EV100 accreditation . Consumer Healthcare 100% sites to achieve good water stewardship by 2025 and reduce overall water use by 20% by 2030 Reduce water use in high water stressed locations by 30% by 2030 90% operational waste reused, recycled, downcycled or incinerated with heat recovery by 2030 100% product packaging recyclable or reusable, including eliminating all problematic and unnecessary plastics, where quality and safety permits by 2025(4) • 100% materials sustainably sourced and deforestation free by 2030 (1) Below the predicted no-effect level (2) Where regulatory obligations allow, and excluding plastics which are critical to product discovery and development and health & safety (3) GSK-owned sites (4) Where quality and safety permit and subject to regulatory compliance Aiming for SBTN accreditation once methodology published 13

View entire presentation